查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1716733

抗心律不整药的全球市场:各类药物，各给药途径，各流通管道，各地区，机会，预测，2018年～2032年

Antiarrhythmic Drugs Market Assessment, By Drug Class, By Route of Administration, By Distribution Channel, By Region, Opportunities and Forecast, 2018-2032F
出版日期: | 出版商: Market Xcel - Markets and Data | 英文 225 Pages | 商品交期: 3-5个工作天内

价格

全球抗心律不整药物市场规模预计将从 2024 年的 11.5 亿美元增长到 2032 年的 18.6 亿美元，预测期内（2025-2032 年）的复合年增长率为 6.22%。市场的成长归因于全球心血管疾病的增加、一般民众对心臟病认识的提高以及製药公司对生产抗心律不整药物的日益重视。世界卫生组织（WHO）估计，心血管疾病每年导致约1790万人死亡。

肥胖、高血压和糖尿病等生活型态相关疾病的负担日益加重，导致对抗心律不整药物的需求不断增加。然而，该类药物中的一些具有较高的副作用风险，包括致心律不整和器官毒性，这可能会限制其使用。此外，预计未来几年世界老龄化人口的增长和心臟治疗技术的进步将推动这些药物的普及。

本报告提供全球抗心律不整药市场相关调查，提供市场概要，以及各类药物，各给药途径，各流通管道，各地区趋势，及加入此市场的主要企业简介等资讯。

目录

第1章 计划的范围和定义

第2章 调查手法

第3章 美国的关税的影响

第4章 摘要整理

第5章 全球抗心律不整药市场预测，2018年～2032年

  • 市场规模分析与预测
  • 市场占有率分析与预测
    • 各类药物
      • 钠流通管道阻断剂
      • β- 阻断剂
      • 钾流通管道阻断剂
      • 钙离子通道阻断剂
      • 其他
    • 各给药途径
      • 口服
      • 非口服
      • 其他
    • 各流通管道
      • 医院药局
      • 零售药局
      • 其他
    • 各地区
      • 北美
      • 欧洲
      • 亚太地区
      • 南美
      • 中东·非洲
    • 各企业市场占有率分析(前五名公司以及其他- 各金额，2024年)
  • 2024年的市场地图分析

第6章 北美的抗心律不整药市场预测，2018年～2032年

第7章 欧洲的抗心律不整药市场预测，2018年～2032年

第8章 亚太地区的抗心律不整药市场预测，2018年～2032年

第9章 南美的抗心律不整药市场预测，2018年～2032年

第10章 中东·非洲的抗心律不整药市场预测，2018年～2032年

第11章 需求供给分析

第12章 价值链分析

第13章 波特的五力分析

第14章 大环境分析

第15章 价格分析

第16章 市场动态

  • 市场促进因素
  • 市场课题

第17章 市场趋势与发展

第18章 法规情形

第19章 临床试验概要

第20章 案例研究

第21章 竞争情形

  • 前五名市场领导的竞争矩阵
  • 前五名参与企业的SWOT分析
  • 前10名市场主要企业的形势
    • Pfizer Inc.
    • Novartis AG
    • Mylan N.V.
    • Baxter International
    • GlaxoSmithKline plc
    • Sanofi S.A.
    • Upsher-Smith Laboratories Inc.
    • AOP Orphan Pharmaceuticals AG
    • AstraZeneca plc
    • Weefsel Pharma Limited

第22章 策略性建议

第23章 关于调查公司·免责声明

Product Code: MX13030

Global antiarrhythmic drugs market is projected to witness a CAGR of 6.22% during the forecast period 2025-2032, growing from USD 1.15 billion in 2024 to USD 1.86 billion in 2032. The market's growth can be attributed to increasing cardiovascular diseases across the globe, rising awareness about cardiac conditions among the general population, and growing focus of pharmaceutical companies on manufacture antiarrhythmic drugs. The World Health Organization (WHO) estimates that cardiovascular diseases are responsible for approximately 17.9 million deaths every year.

The increasing burden of lifestyle-related disorders, including obesity, hypertension, and diabetes, contributes to the growing demand for antiarrhythmic medications. However, some drugs in this class carry a high risk of adverse effects, including proarrhythmia and organ toxicity, which may limit their utilization. Additionally, the expansion of the global aging population and technological advancements in cardiac care are expected to boost the adoption of these drugs in the coming years.

Increasing Prevalence of Cardiovascular Diseases Boosts Market Demand

Rising cases of cardiovascular diseases are influencing the market's growth, with arrhythmias such as atrial fibrillation (AF) being one of the most common types of cardiac conditions. Atrial fibrillation is one of the most common arrhythmias that causes and contributes greatly to incidences of stroke across the globe. Expansion of the aging population and poor lifestyle choices are further anticipated to increase the incidence of AF and other arrhythmias. Thus, healthcare providers are emphasizing early screening, diagnosis, and management of arrhythmia among the patient population.

Advanced diagnostic tools such as wearable ECG monitors and AI-based platforms for rhythm detection are also creating a streamlined, faster, and precise identification of arrhythmia, aiding in initiating treatment protocols that include antiarrhythmic medications in a time-efficient manner. Thus, leading medical device manufacturers focus on developing various arrhythmia monitoring devices. For instance, in January 2025, Medtronic plc announced results from their DEFINE AFib clinical study, demonstrating that Medtronic's LINQ family of insertable cardiac monitors (ICMs), including Reveal LINQ and LINQ II, utilize AI-based algorithms to predict risk thresholds for patients with AF accurately and were able to detect AF episodes and stratify patients into high-risk categories. Such technological integration in patient care increases the accuracy of decision-making, thereby positively impacting the demand for antiarrhythmic medications.

Growth of the Aging Population Supports Market Expansion

The growth of the aging population is a major driver for the expansion of the antiarrhythmic drugs market, as the older population is at a higher risk of developing cardiovascular diseases, including arrhythmias. The World Health Organization estimates that one in six people across the globe will be 60 or older by 2030. The growing elderly population leads to greater demand for effective antiarrhythmic therapies, as these therapeutic solutions are essential for controlling abnormal heart rhythms and reducing the risk of complications such as stroke and heart failure. Additionally, the increased healthcare expenditure, improved access to medical care, and heightened awareness about cardiovascular health among the elderly are further supporting the market's growth.

Retail Pharmacies Account for Significant Share of the Market

The retail pharmacy segment accounts for a major share of the global antiarrhythmic drugs market due to convenience and established patient trust in these institutions. Antiarrhythmic drugs are often prescribed for prolonged treatment in conditions such as atrial fibrillation and ventricular tachycardia; continuous and easy access to these drugs is very important for compliance and, consequently, good management of the diseases. Retail pharmacies provide patients with easy access to fill prescriptions time-efficiently, receive consultative advice from the pharmacist, and obtain refills without the need for hospital visits, further increasing their popularity, especially among the elderly who might be facing mobility issues.

Meanwhile, online pharmacies across the globe are working on increasing the availability of same-day delivery services. In October 2024, Amazon Pharmacy, a division of Amazon.com, Inc., unveiled plans to expand its same-day medication delivery service, doubling the number of cities covered. Leveraging cutting-edge automation and an extensive logistics network, the company seeks to address key challenges in the pharmacy industry, including improving affordability and enhancing convenience for patients.

North America Holds Major Market Share

The market's dominance in the region can be attributed to advanced healthcare infrastructure, high healthcare spending, widespread availability of cardiac diagnostic tools, and the presence of leading pharmaceutical manufacturers. The high prevalence of atrial fibrillation and ventricular arrhythmias, especially among the elderly population, are further driving the utilization of antiarrhythmic drugs. According to the estimates of the Centers for Disease Control and Prevention, approximately 12.1 million people in the United States have atrial fibrillation. This growing burden underscores the critical need for effective pharmacological interventions. Moreover, a large number of clinical trials and Food and Drug Administration (FDA) approvals for cardiovascular drugs originate in the United States, ensuring early market access to novel therapeutic solutions.

As digital health technology integrates more deeply into cardiovascular care, arrhythmia management is expected to become more efficient and tailored, creating new opportunities for drug developers based in the region. The emergence of minimally invasive interventions and hybrid therapy models that combine pharmacological and non-pharmacological approaches could also reshape treatment paradigms, providing lucrative growth opportunities for the market in North America.

Impact of the U.S. Tariff on Global Antiarrhythmic Drugs Market

The recent imposition of tariffs is expected to significantly impact the market and affect the affordability and availability of generic medications. The tariffs are also expected to disrupt pharmaceutical supply chains, especially for generics that usually rely on low-cost active pharmaceutical ingredients. The introduction of tariffs on pharmaceutical imports could also result in delays in sourcing critical drugs and increased costs, resulting in a shortage of essential drugs, including cardiovascular medicines. Pharmaceutical companies may explore alternative sourcing strategies, strengthening partnerships with suppliers across various regions. Additionally, a new dialogue between the policymakers and industry stakeholders will be crucial in navigating the trade complexities associated with the tariffs and ensuring public access to essential medications.

Key Players Landscape and Outlook

The key players in the market are collaborating with leading educational institutions to support the advancement of diagnostic techniques and treatment solutions for cardiac conditions. For instance, the American College of Cardiology (ACC) and Pfizer Inc. are collaborating to provide new grant opportunities for enhancing the identification and diagnosis of transthyretin amyloid cardiomyopathy (ATTR-CM) among heart failure patients, the RFP date for which was April 2, 2025. Pfizer will provide funding, while ACC will oversee the selection of an Expert Review Panel (ERP) and create a community of practice for grantees. This initiative aligns with Pfizer's broader Global Medical Grants & Partnerships (GMGP) strategy, which supports independent healthcare projects to improve patient outcomes in areas where the medical requirements of the patient population are still unmet.

Table of Contents

1. Project Scope and Definitions

2. Research Methodology

3. Impact of the U.S. Tariffs

4. Executive Summary

5. Global Antiarrhythmic Drugs Market Outlook, 2018-2032F

  • 5.1. Market Size Analysis & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share Analysis & Forecast
    • 5.2.1. By Drug Class
      • 5.2.1.1. Sodium Channel Blockers
      • 5.2.1.2. Beta Blockers
      • 5.2.1.3. Potassium Channel Blockers
      • 5.2.1.4. Calcium Channel Blockers
      • 5.2.1.5. Others
    • 5.2.2. By Route of Administration
      • 5.2.2.1. Oral
      • 5.2.2.2. Parenteral
      • 5.2.2.3. Others
    • 5.2.3. By Distribution Channel
      • 5.2.3.1. Hospital Pharmacies
      • 5.2.3.2. Retail Pharmacies
      • 5.2.3.3. Others
    • 5.2.4. By Region
      • 5.2.4.1. North America
      • 5.2.4.2. Europe
      • 5.2.4.3. Asia-Pacific
      • 5.2.4.4. South America
      • 5.2.4.5. Middle East and Africa
    • 5.2.5. By Company Market Share Analysis (Top 5 Companies and Others - By Value, 2024)
  • 5.3. Market Map Analysis, 2024
    • 5.3.1. By Drug Class
    • 5.3.2. By Route of Administration
    • 5.3.3. By Distribution Channel
    • 5.3.4. By Region

6. North America Antiarrhythmic Drugs Market Outlook, 2018-2032F

  • 6.1. Market Size Analysis & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share Analysis & Forecast
    • 6.2.1. By Drug Class
      • 6.2.1.1. Sodium Channel Blockers
      • 6.2.1.2. Beta Blockers
      • 6.2.1.3. Potassium Channel Blockers
      • 6.2.1.4. Calcium Channel Blockers
      • 6.2.1.5. Others
    • 6.2.2. By Route of Administration
      • 6.2.2.1. Oral
      • 6.2.2.2. Parenteral
      • 6.2.2.3. Others
    • 6.2.3. By Distribution Channel
      • 6.2.3.1. Hospital Pharmacies
      • 6.2.3.2. Retail Pharmacies
      • 6.2.3.3. Others
    • 6.2.4. By Country Share
      • 6.2.4.1. United States
      • 6.2.4.2. Canada
      • 6.2.4.3. Mexico
  • 6.3. Country Market Assessment
    • 6.3.1. United States Antiarrhythmic Drugs Market Outlook, 2018-2032F*
      • 6.3.1.1. Market Size Analysis & Forecast
        • 6.3.1.1.1. By Value
          • 6.3.1.1.1.1. Market Share Analysis & Forecast
        • 6.3.1.1.2. By Drug Class
          • 6.3.1.1.2.1. Sodium Channel Blockers
          • 6.3.1.1.2.2. Beta Blockers
          • 6.3.1.1.2.3. Potassium Channel Blockers
          • 6.3.1.1.2.4. Calcium Channel Blockers
          • 6.3.1.1.2.5. Others
        • 6.3.1.1.3. By Route of Administration
          • 6.3.1.1.3.1. Oral
          • 6.3.1.1.3.2. Parenteral
          • 6.3.1.1.3.3. Others
        • 6.3.1.1.4. By Distribution Channel
          • 6.3.1.1.4.1. Hospital Pharmacies
          • 6.3.1.1.4.2. Retail Pharmacies
          • 6.3.1.1.4.3. Others
    • 6.3.2. Canada
    • 6.3.3. Mexico

All segments will be provided for all regions and countries covered

7. Europe Antiarrhythmic Drugs Market Outlook, 2018-2032F

  • 7.1. Germany
  • 7.2. France
  • 7.3. Italy
  • 7.4. United Kingdom
  • 7.5. Russia
  • 7.6. Netherlands
  • 7.7. Spain
  • 7.8. Turkey
  • 7.9. Poland

8. Asia-Pacific Antiarrhythmic Drugs Market Outlook, 2018-2032F

  • 8.1. India
  • 8.2. China
  • 8.3. Japan
  • 8.4. Australia
  • 8.5. Vietnam
  • 8.6. South Korea
  • 8.7. Indonesia
  • 8.8. Philippines

9. South America Antiarrhythmic Drugs Market Outlook, 2018-2032F

  • 9.1. Brazil
  • 9.2. Argentina

10. Middle East and Africa Antiarrhythmic Drugs Market Outlook, 2018-2032F

  • 10.1. Saudi Arabia
  • 10.2. UAE
  • 10.3. South Africa

11. Demand Supply Analysis

12. Value Chain Analysis

13. Porter's Five Forces Analysis

14. PESTLE Analysis

15. Pricing Analysis

16. Market Dynamics

  • 16.1. Market Drivers
  • 16.2. Market Challenges

17. Market Trends and Developments

18. Regulatory Landscape

19. Overview of Clinical Trials

20. Case Studies

21. Competitive Landscape

  • 21.1. Competition Matrix of Top 5 Market Leaders
  • 21.2. SWOT Analysis for Top 5 Players
  • 21.3. Key Players Landscape for Top 10 Market Players
    • 21.3.1. Pfizer Inc.
      • 21.3.1.1. Company Details
      • 21.3.1.2. Key Management Personnel
      • 21.3.1.3. Products and Services
      • 21.3.1.4. Financials (As Reported)
      • 21.3.1.5. Key Market Focus and Geographical Presence
      • 21.3.1.6. Recent Developments/Collaborations/Partnerships/Mergers and Acquisition
    • 21.3.2. Novartis AG
    • 21.3.3. Mylan N.V.
    • 21.3.4. Baxter International
    • 21.3.5. GlaxoSmithKline plc
    • 21.3.6. Sanofi S.A.
    • 21.3.7. Upsher-Smith Laboratories Inc.
    • 21.3.8. AOP Orphan Pharmaceuticals AG
    • 21.3.9. AstraZeneca plc
    • 21.3.10. Weefsel Pharma Limited

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

22. Strategic Recommendations

23. About Us and Disclaimer

List of Tables

  • Table 1. Competition Matrix of Top 5 Market Leaders
  • Table 2. Mergers & Acquisitions/ Joint Ventures (If Applicable)
  • Table 3. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

  • Figure 1. Global Antiarrhythmic Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 2. Global Antiarrhythmic Drugs Market Share (%), By Drug Class, 2018-2032F
  • Figure 3. Global Antiarrhythmic Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 4. Global Antiarrhythmic Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 5. Global Antiarrhythmic Drugs Market Share (%), By Region, 2018-2032F
  • Figure 6. North America Antiarrhythmic Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 7. North America Antiarrhythmic Drugs Market Share (%), By Drug Class, 2018-2032F
  • Figure 8. North America Antiarrhythmic Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 9. North America Antiarrhythmic Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 10. North America Antiarrhythmic Drugs Market Share (%), By Country, 2018-2032F
  • Figure 11. United States Antiarrhythmic Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 12. United States Antiarrhythmic Drugs Market Share (%), By Drug Class, 2018-2032F
  • Figure 13. United States Antiarrhythmic Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 14. United States Antiarrhythmic Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 15. Canada Antiarrhythmic Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 16. Canada Antiarrhythmic Drugs Market Share (%), By Drug Class, 2018-2032F
  • Figure 17. Canada Antiarrhythmic Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 18. Canada Antiarrhythmic Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 19. Mexico Antiarrhythmic Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 20. Mexico Antiarrhythmic Drugs Market Share (%), By Drug Class, 2018-2032F
  • Figure 21. Mexico Antiarrhythmic Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 22. Mexico Antiarrhythmic Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 23. Europe Antiarrhythmic Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 24. Europe Antiarrhythmic Drugs Market Share (%), By Drug Class, 2018-2032F
  • Figure 25. Europe Antiarrhythmic Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 26. Europe Antiarrhythmic Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 27. Europe Antiarrhythmic Drugs Market Share (%), By Country, 2018-2032F
  • Figure 28. Germany Antiarrhythmic Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 29. Germany Antiarrhythmic Drugs Market Share (%), By Drug Class, 2018-2032F
  • Figure 30. Germany Antiarrhythmic Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 31. Germany Antiarrhythmic Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 32. France Antiarrhythmic Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 33. France Antiarrhythmic Drugs Market Share (%), By Drug Class, 2018-2032F
  • Figure 34. France Antiarrhythmic Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 35. France Antiarrhythmic Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 36. Italy Antiarrhythmic Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 37. Italy Antiarrhythmic Drugs Market Share (%), By Drug Class, 2018-2032F
  • Figure 38. Italy Antiarrhythmic Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 39. Italy Antiarrhythmic Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 40. United Kingdom Antiarrhythmic Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 41. United Kingdom Antiarrhythmic Drugs Market Share (%), By Drug Class, 2018-2032F
  • Figure 42. United Kingdom Antiarrhythmic Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 43. United Kingdom Antiarrhythmic Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 44. Russia Antiarrhythmic Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 45. Russia Antiarrhythmic Drugs Market Share (%), By Drug Class, 2018-2032F
  • Figure 46. Russia Antiarrhythmic Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 47. Russia Antiarrhythmic Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 48. Netherlands Antiarrhythmic Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 49. Netherlands Antiarrhythmic Drugs Market Share (%), By Drug Class, 2018-2032F
  • Figure 50. Netherlands Antiarrhythmic Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 51. Netherlands Antiarrhythmic Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 52. Spain Antiarrhythmic Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 53. Spain Antiarrhythmic Drugs Market Share (%), By Drug Class, 2018-2032F
  • Figure 54. Spain Antiarrhythmic Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 55. Spain Antiarrhythmic Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 56. Turkey Antiarrhythmic Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 57. Turkey Antiarrhythmic Drugs Market Share (%), By Drug Class, 2018-2032F
  • Figure 58. Turkey Antiarrhythmic Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 59. Turkey Antiarrhythmic Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 60. Poland Antiarrhythmic Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 61. Poland Antiarrhythmic Drugs Market Share (%), By Drug Class, 2018-2032F
  • Figure 62. Poland Antiarrhythmic Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 63. Poland Antiarrhythmic Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 64. Asia-Pacific Antiarrhythmic Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 65. Asia-Pacific Antiarrhythmic Drugs Market Share (%), By Drug Class, 2018-2032F
  • Figure 66. Asia-Pacific Antiarrhythmic Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 67. Asia-Pacific Antiarrhythmic Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 68. Asia-Pacific Antiarrhythmic Drugs Market Share (%), By Country, 2018-2032F
  • Figure 69. India Antiarrhythmic Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 70. India Antiarrhythmic Drugs Market Share (%), By Drug Class, 2018-2032F
  • Figure 71. India Antiarrhythmic Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 72. India Antiarrhythmic Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 73. China Antiarrhythmic Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 74. China Antiarrhythmic Drugs Market Share (%), By Drug Class, 2018-2032F
  • Figure 75. China Antiarrhythmic Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 76. China Antiarrhythmic Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 77. Japan Antiarrhythmic Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 78. Japan Antiarrhythmic Drugs Market Share (%), By Drug Class, 2018-2032F
  • Figure 79. Japan Antiarrhythmic Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 80. Japan Antiarrhythmic Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 81. Australia Antiarrhythmic Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 82. Australia Antiarrhythmic Drugs Market Share (%), By Drug Class, 2018-2032F
  • Figure 83. Australia Antiarrhythmic Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 84. Australia Antiarrhythmic Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 85. Vietnam Antiarrhythmic Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 86. Vietnam Antiarrhythmic Drugs Market Share (%), By Drug Class, 2018-2032F
  • Figure 87. Vietnam Antiarrhythmic Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 88. Vietnam Antiarrhythmic Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 89. South Korea Antiarrhythmic Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 90. South Korea Antiarrhythmic Drugs Market Share (%), By Drug Class, 2018-2032F
  • Figure 91. South Korea Antiarrhythmic Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 92. South Korea Antiarrhythmic Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 93. Indonesia Antiarrhythmic Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 94. Indonesia Antiarrhythmic Drugs Market Share (%), By Drug Class, 2018-2032F
  • Figure 95. Indonesia Antiarrhythmic Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 96. Indonesia Antiarrhythmic Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 97. Philippines Antiarrhythmic Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 98. Philippines Antiarrhythmic Drugs Market Share (%), By Drug Class, 2018-2032F
  • Figure 99. Philippines Antiarrhythmic Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 100. Philippines Antiarrhythmic Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 101. South America Antiarrhythmic Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 102. South America Antiarrhythmic Drugs Market Share (%), By Drug Class, 2018-2032F
  • Figure 103. South America Antiarrhythmic Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 104. South America Antiarrhythmic Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 105. South America Antiarrhythmic Drugs Market Share (%), By Country, 2018-2032F
  • Figure 106. Brazil Antiarrhythmic Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 107. Brazil Antiarrhythmic Drugs Market Share (%), By Drug Class, 2018-2032F
  • Figure 108. Brazil Antiarrhythmic Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 109. Brazil Antiarrhythmic Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 110. Argentina Antiarrhythmic Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 111. Argentina Antiarrhythmic Drugs Market Share (%), By Drug Class, 2018-2032F
  • Figure 112. Argentina Antiarrhythmic Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 113. Argentina Antiarrhythmic Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 114. Middle East & Africa Antiarrhythmic Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 115. Middle East & Africa Antiarrhythmic Drugs Market Share (%), By Drug Class, 2018-2032F
  • Figure 116. Middle East & Africa Antiarrhythmic Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 117. Middle East & Africa Antiarrhythmic Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 118. Middle East & Africa Antiarrhythmic Drugs Market Share (%), By Country, 2018-2032F
  • Figure 119. Saudi Arabia Antiarrhythmic Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 120. Saudi Arabia Antiarrhythmic Drugs Market Share (%), By Drug Class, 2018-2032F
  • Figure 121. Saudi Arabia Antiarrhythmic Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 122. Saudi Arabia Antiarrhythmic Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 123. UAE Antiarrhythmic Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 124. UAE Antiarrhythmic Drugs Market Share (%), By Drug Class, 2018-2032F
  • Figure 125. UAE Antiarrhythmic Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 126. UAE Antiarrhythmic Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 127. South Africa Antiarrhythmic Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 128. South Africa Antiarrhythmic Drugs Market Share (%), By Drug Class, 2018-2032F
  • Figure 129. South Africa Antiarrhythmic Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 130. South Africa Antiarrhythmic Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 131. By Drug Class Map-Market Size (USD Billion) & Growth Rate (%), 2024
  • Figure 132. By Route of Administration Map-Market Size (USD Billion) & Growth Rate (%), 2024
  • Figure 133. By Distribution Channel Map-Market Size (USD Billion) & Growth Rate (%), 2024
  • Figure 134. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2024